Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline

Journal of Travel Medicine

Volumn 22, Issue 6, 2015, Pages 383-388

  Terrell, Andrew G ^a   Forde, Mike E ^b   Firth, Richard ^b   Ross, David A ^b  

^a DMS Whittington   (United Kingdom)

^b Army Health Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; MEFLOQUINE; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ARTICLE; BACKACHE; BODY TEMPERATURE DISORDER; CHEST INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOCUMENTATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERYTHEMA; FATIGUE; HEADACHE; HOT SWEAT; HUMAN; KENYA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MEDIAL TIBIAL STRESS SYNDROME; MOUTH ULCER; MUSCLE RIGIDITY; NAUSEA; OUTCOME ASSESSMENT; PANIC; PATHOGEN LOAD; PRURITUS; QUESTIONNAIRE; RASH; SELF REPORT; SENSORY DYSFUNCTION; SLEEP DISORDER; SORE THROAT; SYMPTOMATOLOGY; THORAX PAIN; UNPLEASANT DREAM; VERTIGO; VISUAL DISORDER; VOMITING; WORK CAPACITY; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; GREAT BRITAIN; SOLDIER; WORK;

ANTIMALARIALS; CHEMOPREVENTION; COHORT STUDIES; DOXYCYCLINE; GREAT BRITAIN; HUMANS; KENYA; MALARIA; MEFLOQUINE; MILITARY PERSONNEL; SELF REPORT; WORK;

EID: 84945138853     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12232     Document Type: Article

References (35)

1. National Travel Health Network and Centre (NaTHNaC). Country information-Kenya. Available at: http://nathnac.org/ds/c-pages/country-page-ke.htm. (Accessed 2014 Jul 30).
2. Chiodini PL, Field VK, Hill DR, et al., Guidelines for malaria prevention in travellers from the United Kingdom. London, Public Health England, July 2013. Available at: http://www.hpa.org.uk/infections/topics-az/malaria/guidelines.htm. (Accessed 2014 Jul 30).
3. Reisinger EC, Horstmann RD, Dietrich M,. Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg 1989; 83: 474-477.
4. Arthur JD, Echeverria P, Shanks GD, et al., A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 1990; 43: 608-613.
5. Salako LA, Adio RA, Walker O, et al., Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study. Ann Trop Med Parasitol 1992; 86: 575-581.
6. Kozarsky P, Eaton M,. Use of mefloquine for malarial chemoprophylaxis in its first year of availability in the United States. Clin Infect Dis 1993; 16: 185-186.
7. Lobel HO, Miani M, Eng T, et al., Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341: 848-851.
8. Rombo L, Angel VH, Friman G, et al., Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. Trop Med Parasitol 1993; 44: 254-256.
9. Jaspers CA, Hopperus Buma AP, van Thiel PP, et al., Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55: 230-234.
10. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ,. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313: 525-528.
11. Corbett EL, Doherty JP, Behrens RH,. Adverse events associated with mefloquine: study in returned travellers confirms authors' findings. BMJ 1996; 313: 1552.
12. Schlagenhauf P, Steffen R, Lobel H, et al., Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996; 1: 485-494.
13. Phillips MA, Kass RB,. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996; 3: 40-45.
14. Croft AM, Clayton TC, World MJ,. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997; 91: 199-203.
15. Ohrt C, Richie TL, Widjaja H, et al., Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 963-972.
16. Carme B, Peguet C, Nevez G,. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997; 2: 953-956.
17. Hoebe C, de Munter J, Thijs C,. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52: 269-275.
18. Peragallo MS, Sabatinelli G, Sarnicola G,. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93: 73-77.
19. Overbosch D, Schilthuis H, Bienzle U, et al., Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015-1021.
20. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al., Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002; 58: 441-445.
21. Schlagenhauf P, Tschopp A, Johnson R, et al., Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003; 327: 1078-1081.
22. Matsumura T, Fujii T, Miura T, et al., Questionnaire-based analysis of mefloquine chemoprophylaxis for malaria in a Japanese population. J Infect Chemother 2005; 11: 196-198.
23. Sonmez A, Harlak A, Kilic S, et al., The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect 2005; 1: 253-258.
24. Mizuno Y, Kudo K, Kano S,. Chemoprophylaxis according to the guidelines on malaria prevention for Japanese overseas travellers. Southeast Asian J Trop Med Public Health 2006; 37 (Suppl 3): 11-14.
25. Korhonen C, Peterson K, Bruder C, Jung P,. Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers. Am J Prev Med 2007; 33: 194-199.
26. Nasveld PE, Edstein MD, Reid M, et al., Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother 2010; 54: 792-798.
27. Steffen R, Fuchs E, Schildknecht J, et al., Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341: 1299-1303.
28. Boudreau E, Schuster B, Sanchez J, et al., Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44: 257-265.
29. Hopperus Buma AP, van Thiel PP, Lobel HO, et al., Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173: 1506-1509.
30. Huzly D, Schönfeld C, Beuerle W, Bienzle U,. Malaria chemoprophylaxis in German tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996; 3: 148-155.
31. Davis TM, Dembo LG, Kaye-Eddie SA, et al., Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers, a double blind, placebo controlled trial. Br J Clin Pharmacol 1996; 42: 415-421.
32. Petersen E, Ronne T, Ronn A, et al., Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med 2000; 7: 79-84.
33. Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD,. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust 2005; 182: 168-171.
34. Pages F, Boutin JP, Meynard JB, et al., Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop Med Int Health 2002; 7: 919-924.
35. World Health Organization. Kenya in World Malaria Report 2014. Available at: http://www.who.int/malaria/publications/country&x02010;profiles/profile-ken-en.pdf?ua&x0003D;1. (Accessed 2015 Mar 27).